List view / Grid view
A significant obstacle still faced in oncology is damage to healthy cells inflicted during treatment, which robs patients of their quality of life while battling cancer. Targeted radionuclide therapy (TRT) is a type of radiomolecular precision oncology that addresses this issue by deploying cancer-killing radiation directly to tumour cells, with…
The brain is protected by the blood-brain barrier, a multi-layered structure which helps to protect it from the invasion of pathogens or unwanted substances and limits drug transport into the brain via the bloodstream. Here, Dr Oliver Ernst and Dr Heiko Manninga from German biotech company NEUWAY Pharma share details of…
Lubrizol Life Science Health colleagues Nick DiFranco, Global Market Segment Manager for Oral Treatments, and Joey Glassco, Senior Global Market Manager for Parenteral Drug Delivery, explore the use of amorphous solid dispersions and polymeric micelles for solubility enhancement.
Articles featured in this in-depth focus discuss a technology enabling drugs to be delivered across the blood-brain barrier, the potential of targeted radionuclide therapy as a precision oncology treatment and novel bioconjugation methods to improve biologics drug delivery.
Articles in this in-depth focus explore the applications of portable spectrometers and review their critical features, as well as comparing the results of standard and miniaturised NIR spectroscopy sensors in medicinal plant QC.
In our latest journal, discover the innovations enabling drugs to be delivered across the blood-brain barrier, the challenges associated with downstream purification of cell and gene therapies, as well as applications of NIR spectroscopy in ingredient analysis. Also featured in this issue, explore the development and future potential of radiomolecular…
European Pharmaceutical Review investigates the financial results of some of the top 10 pharma and biopharma companies worldwide.
In this article, Karen Ooms, Head of Statistics at Quanticate, compares the rule- and model-based approaches to Phase I trial design, exploring their benefits and weaknesses in defining maximum tolerated dose for oncology products.
The impending ‘Bio Revolution’, with the microbiome at its foundation, offers ground-breaking solutions and a wealth of opportunity in data science and bioinformatics, explains Anthony Finbow of Eagle Genomics.
Here, EPR’s Hannah Balfour examines the trends that look set to shape clinical research in 2022, with comment from Aman Khera, VP and Global Head of Regulatory Strategy at Worldwide Clinical Trials.
In this article, Sarah Bly and Aman Khera of Worldwide Clinical Trials break down the seven key differences between the EU Clinical Trial Directive and new EU Clinical Trial Regulation, discussing when and how sponsors should begin submitting their trials through the new CTIS portal system.
What are the top six challenges facing pharmaceutical and biopharmaceutical manufacturers in 2022? We spoke to representatives from four contract manufacturing and development organisations (CDMOs) – Samsung Biologics, Lonza, MedPharm and Genezen – to find out.
Here we run down four new research collaborations in the cell and gene therapy sector, announced by Bayer, BMS, Pfizer and Moderna.
Effective vancomycin concentrations can be delivered locally to methicillin-resistant Staphylococcus aureus (MRSA)-infected sites of the skin with the use of miniaturised needles. This presents opportunities for targeted delivery of medication for focal skin diseases. Here, Georgios A Sotiriou and Liv Eidsmo of the Karolinska Institutet discuss some of them.
When the pandemic broke out in 2020, pharmaceutical supply chains showed signs of potential failure across the continent. Now, with COVID-19 cases rising once more, and an end to the problem not yet in sight, we discuss with Medicines for Europe how these supply chains are faring, almost two years…
